Financials Vivos Therapeutics, Inc.
Equities
VVOS
US92859E2072
Medical Equipment, Supplies & Distribution
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
2.23 USD | -6.30% |
|
-0.89% | -82.07% |
Valuation
Fiscal Period: December | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
---|---|---|---|---|---|---|
Capitalization 1 | 104.4 | 51.78 | 9.251 | 14.89 | 7.197 | - |
Enterprise Value (EV) 1 | 104.4 | 51.78 | 9.251 | 14.89 | 7.197 | 7.197 |
P/E ratio | -4.22 x | -2.34 x | -0.39 x | -1.12 x | -0.54 x | -0.99 x |
Yield | - | - | - | - | - | - |
Capitalization / Revenue | 7.99 x | 3.07 x | 0.58 x | 1.08 x | 0.48 x | 0.39 x |
EV / Revenue | 7.99 x | 3.07 x | 0.58 x | 1.08 x | 0.48 x | 0.39 x |
EV / EBITDA | - | - | -379,725 x | - | - | - |
EV / FCF | - | - | - | - | - | - |
FCF Yield | - | - | - | - | - | - |
Price to Book | 6.36 x | - | - | - | - | - |
Nbr of stocks (in thousands) | 707 | 920 | 920 | 1,197 | 3,227 | - |
Reference price 2 | 147.8 | 56.25 | 10.05 | 12.44 | 2.230 | 2.230 |
Announcement Date | 25/03/21 | 31/03/22 | 30/03/23 | 28/03/24 | - | - |
Income Statement Evolution (Annual data)
Fiscal Period: December | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
---|---|---|---|---|---|---|
Net sales 1 | 13.07 | 16.88 | 16.02 | 13.8 | 14.9 | 18.41 |
EBITDA | - | - | -24.36 | - | - | - |
EBIT 1 | -8.709 | -20.38 | -25.03 | -17.3 | -12.4 | -10.51 |
Operating Margin | -66.65% | -120.71% | -156.21% | -125.32% | -83.22% | -57.09% |
Earnings before Tax (EBT) 1 | -12.06 | -20.29 | -23.84 | -13.58 | -12.3 | -10.53 |
Net income 1 | -17.99 | -20.29 | -23.84 | -13.58 | -12.3 | -10.53 |
Net margin | -137.67% | -120.15% | -148.81% | -98.42% | -82.55% | -57.22% |
EPS 2 | -35.00 | -24.00 | -26.00 | -11.14 | -4.140 | -2.260 |
Free Cash Flow | - | - | - | - | - | - |
FCF margin | - | - | - | - | - | - |
FCF Conversion (EBITDA) | - | - | - | - | - | - |
FCF Conversion (Net income) | - | - | - | - | - | - |
Dividend per Share | - | - | - | - | - | - |
Announcement Date | 25/03/21 | 31/03/22 | 30/03/23 | 28/03/24 | - | - |
Income Statement Evolution (Quarterly data)
Fiscal Period: December | 2021 Q4 | 2022 Q1 | 2022 Q3 | 2022 Q4 | 2023 Q1 | 2023 Q2 | 2023 Q3 | 2023 Q4 | 2024 Q1 | 2024 Q2 | 2024 Q3 | 2024 Q4 | 2025 Q1 | 2025 Q2 |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Net sales 1 | 4.394 | 3.46 | 4.246 | 3.95 | 3.857 | 3.395 | 3.301 | 3.248 | 3.419 | 3.6 | 3.8 | 4.1 | 4 | 4.2 |
EBITDA | - | - | - | -5.894 | - | -4.369 | -3.339 | - | - | - | - | - | - | - |
EBIT 1 | -7.411 | -6.823 | -5.407 | -6.063 | -5.005 | -4.517 | -3.489 | -4.284 | -3.785 | -3.1 | -2.9 | -2.6 | -2.5 | -2.3 |
Operating Margin | -168.65% | -197.2% | -127.34% | -153.49% | -129.76% | -133.05% | -105.7% | -131.9% | -110.7% | -86.11% | -76.32% | -63.41% | -62.5% | -54.76% |
Earnings before Tax (EBT) 1 | -7.393 | -5.515 | -5.434 | -6.089 | -1.703 | -5.528 | -2.093 | -4.259 | -3.763 | -3.1 | -2.9 | -2.6 | -2.5 | -2.3 |
Net income 1 | -7.393 | -5.515 | -5.434 | -6.089 | -1.703 | -5.528 | -2.093 | -4.259 | -3.763 | -3.1 | -2.9 | -2.6 | -2.5 | -2.3 |
Net margin | -168.24% | -159.39% | -127.98% | -154.15% | -44.15% | -162.83% | -63.41% | -131.13% | -110.06% | -86.11% | -76.32% | -63.41% | -62.5% | -54.76% |
EPS 2 | -8.500 | -6.500 | -6.500 | -5.000 | -1.750 | -4.500 | -1.750 | -3.050 | -1.630 | -1.050 | -0.9600 | -0.8700 | -0.8500 | -0.7800 |
Dividend per Share | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Announcement Date | 31/03/22 | 16/05/22 | 20/12/22 | 30/03/23 | 08/06/23 | 16/08/23 | 14/11/23 | 28/03/24 | 14/05/24 | - | - | - | - | - |
Balance Sheet Analysis
Fiscal Period: December | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
---|---|---|---|---|---|---|
Net Debt | - | - | - | - | - | - |
Net Cash position | - | - | - | - | - | - |
Leverage (Debt/EBITDA) | - | - | - | - | - | - |
Free Cash Flow | - | - | - | - | - | - |
ROE (net income / shareholders' equity) | -257% | - | - | - | - | - |
ROA (Net income/ Total Assets) | -109% | - | - | - | - | - |
Assets 1 | 16.44 | - | - | - | - | - |
Book Value Per Share | 23.20 | - | - | - | - | - |
Cash Flow per Share | - | - | - | - | - | - |
Capex 1 | 0.12 | - | 0.92 | - | 0.6 | 0.6 |
Capex / Sales | 0.92% | - | 5.77% | - | 4.03% | 3.26% |
Announcement Date | 25/03/21 | 31/03/22 | 30/03/23 | 28/03/24 | - | - |
EPS & Dividend
Year-on-year evolution of the PER
Change in Enterprise Value/EBITDA
![Consensus](/images/consensus_flch.gif)
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
-82.07% | 7.2M | |
+75.69% | 12.57B | |
+11.91% | 6.96B | |
-29.01% | 6.92B | |
+9.77% | 5.24B | |
-20.60% | 4.6B | |
+13.02% | 4.02B | |
-29.14% | 2.67B | |
+27.73% | 2.05B | |
-1.86% | 1.99B |
- Stock Market
- Equities
- VVOS Stock
- Financials Vivos Therapeutics, Inc.